1Department of Radiation Oncology, Mayo Clinic, Rochester, Minnesota 2Department of Surgical Oncology, MD Anderson Cancer Center, Houston, Texas 3Department of Colon and Rectal Surgery, Mayo Clinic, Rochester, Minnesota.
Dis Colon Rectum. 2014 Apr;57(4):442-8. doi: 10.1097/DCR.0000000000000071.
For patients with residual or recurrent squamous-cell carcinoma of the anus after primary chemoradiotherapy, the standard treatment is surgical salvage. Patients with unresectable or borderline unresectable disease have poor outcomes, thus adjunctive treatments should be explored.
The aim of this study is to report outcomes for patients with residual/recurrent anal cancer treated with multimodality therapy including salvage surgical resection and intraoperative radiotherapy.
This is an observational study.
This study was conducted at a tertiary referral center.
Thirty-two patients were treated between 1993 and 2012. Median age was 53 years (range, 34-87). Salvage treatment was performed for residual disease (n = 9), first recurrence (n = 17), or second recurrence (n = 6) after primary chemoradiotherapy.
Patients with recurrent disease received preoperative external beam reirradiation with concurrent chemotherapy. All patients underwent salvage surgical resection and intraoperative radiotherapy. Extent of surgical resection was R0 (negative margins, n = 16), R1 (microscopic residual, n = 13), or R2 (macroscopic residual, n = 3). The median intraoperative radiotherapy dose was 12.5 Gy.
Treatment-related adverse events were classified according to the National Cancer Institute - Common Toxicity Criteria. Overall and disease-free survival were estimated by using the Kaplan-Meier technique. Central, local-regional, and distant failure were estimated by the use of the cumulative incidence method.
Median length of hospital stay was 9 days. Mortality at 30 days after surgery and intraoperative radiotherapy was 0%. Fifteen patients (47%) experienced a total of 16 grade 3 treatment-related adverse events (wound complication (n = 6), bowel obstruction (n = 5), and ureteral obstruction (n = 3)). The 5-year estimates of overall and disease-free survival were 23% and 17%. The 5-year estimates of central, local-regional, and distant failure were 21%, 51%, and 40%.
This was a single-institution observational study with limited patient numbers.
In this heavily pretreated, high-risk patient population, multimodality therapy including salvage surgery and intraoperative radiotherapy was associated with long-term survival in a small, but significant subset of patients.
对于接受原发性放化疗后残留或复发的肛门鳞癌患者,标准治疗是手术挽救。患有不可切除或临界不可切除疾病的患者预后较差,因此应探索辅助治疗。
本研究旨在报告采用包括挽救性手术切除和术中放疗在内的多模态治疗治疗残留/复发肛门癌患者的结果。
这是一项观察性研究。
本研究在三级转诊中心进行。
1993 年至 2012 年期间共治疗了 32 名患者。中位年龄为 53 岁(范围 34-87 岁)。挽救性治疗用于原发性放化疗后残留疾病(n=9)、首次复发(n=17)或第二次复发(n=6)。
复发疾病患者接受术前外照射再放疗联合化疗。所有患者均行挽救性手术切除和术中放疗。手术切除范围为 R0(阴性边缘,n=16)、R1(镜下残留,n=13)或 R2(肉眼残留,n=3)。术中放疗的中位剂量为 12.5Gy。
根据国家癌症研究所常见毒性标准对治疗相关不良事件进行分类。通过 Kaplan-Meier 技术估计总生存率和无病生存率。采用累积发生率法估计中心、局部区域和远处失败。
中位住院时间为 9 天。术后和术中放疗 30 天死亡率为 0%。15 名患者(47%)共发生 16 例 3 级治疗相关不良事件(伤口并发症(n=6)、肠梗阻(n=5)和输尿管梗阻(n=3))。总生存率和无病生存率的 5 年估计值分别为 23%和 17%。中心、局部区域和远处失败的 5 年估计值分别为 21%、51%和 40%。
这是一项单中心观察性研究,患者人数有限。
在这个经过大量预处理的高危患者人群中,包括挽救性手术和术中放疗在内的多模态治疗在一小部分患者中取得了长期生存,尽管这部分患者数量较少,但意义重大。